Livzon Pharmaceutical Group Inc. (HKG:1513)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
37.40
-0.86 (-2.25%)
Sep 9, 2025, 1:43 PM HKT
-2.25%
Market Cap38.17B
Revenue (ttm)12.93B
Net Income (ttm)2.38B
Shares Outn/a
EPS (ttm)2.62
PE Ratio16.04
Forward PE15.91
Dividend1.20 (3.16%)
Ex-Dividend DateJun 13, 2025
Volume698,350
Average Volume1,963,335
Open38.14
Previous Close38.26
Day's Range37.28 - 38.78
52-Week Range24.50 - 41.85
Beta0.27
RSI56.89
Earnings DateAug 21, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric... [Read more]

Sector Healthcare
Founded 1985
Employees 9,067
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1513
Full Company Profile

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.